购物车
- 全部删除
- 您的购物车当前为空
BMS-536924 (BMS 536924) 是一种具有口服活性,竞争性和选择性的胰岛素样生长因子受体激酶和胰岛素受体抑制剂,IC50分别为 100 nM 和 73 nM。它具有抗癌活性。
为众多的药物研发团队赋能,
让新药发现更简单!
BMS-536924 (BMS 536924) 是一种具有口服活性,竞争性和选择性的胰岛素样生长因子受体激酶和胰岛素受体抑制剂,IC50分别为 100 nM 和 73 nM。它具有抗癌活性。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 263 | 现货 | |
5 mg | ¥ 797 | 现货 | |
10 mg | ¥ 1,430 | 现货 | |
25 mg | ¥ 2,450 | 现货 | |
50 mg | ¥ 3,620 | 现货 | |
100 mg | ¥ 5,160 | 现货 | |
200 mg | ¥ 6,950 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 838 | 现货 |
产品描述 | BMS-536924 (BMS 536924) is an ATP-competitive IGF-1R/IR inhibitor with IC50 of 100 nM/73 nM, modest activity for Mek, Fak, and Lck with very little activity for Akt1, MAPK1/2. |
靶点活性 | IGF-1R:100 nM, Insulin receptor:73 nM |
体外活性 | BMS-536924能够以IC50值分别为150 nM和341 nM抑制FAK和Lck。此外,BMS-536924抑制细胞增殖并干扰Akt和MAPK的磷酸化。[1]在MCF10A细胞中,BMS-536924抑制由IGF-I激发的IGF-1R信号传导,并阻断CD8-IGF-1R-MCF10A的IGF-1R固有活性。用1μM BMS-536924预处理MCF10A细胞,能完全阻断IGF-I对IGF-1R磷酸化的激活。IGF-I激发会增加ERK1/2、GSK3β和Akt的磷酸化,BMS-536924抑制这种配体诱导的磷酸化。在CD8-IGF-1R-MCF10A细胞中,BMS-536924处理导致磷酸化的剂量依赖性抑制,0.01 μM和0.1 μM下为部分抑制,1 μM浓度时实现完全受体抑制。在孵育后最早10分钟可观察到IGF-1R磷酸化的最大抑制。BMS-536924保持抑制IGF-1R磷酸化的能力长达48小时。BMS-536924添加后,从1小时开始时间依赖性地抑制Akt磷酸化,并在48小时完全阻断Akt激活。[2] BMS-536924在包括TC32、HT1080/S、SK-LMS-1、H513和CTR细胞系在内的一系列癌细胞系中显示出抗增殖活性。IGF-I/胰岛素刺激导致pIGF-1R/pIR激活,在Rh41和Rh36细胞系中,这种激活被BMS-536924以相似的效力抑制。在用BMS-536924处理的Rh41细胞中,程序性细胞死亡4(PDCD4)、聚(ADP-核糖)聚合酶(PARP)的切割和caspase-3的表达上调。[3] |
体内活性 | 经口给药BMS-536924以100-300 mpk剂量强烈抑制IGR-1R Sal肿瘤模型。在非转基因Colo205人结肠癌模型中亦观察到疗效。通过每日一次(100-300 mpk)或每日两次(50, 100 mpk)给药方式,展现了对该肿瘤模型的抗肿瘤活性。口服葡萄糖耐量试验(OGTT)显示,100 mpk(b.i.d.)的剂量在葡萄糖挑战后显著升高葡萄糖水平。通过在聚乙二醇400和水(80:20 v/v)中口服给予,测定了BMS-536924在小鼠、大鼠、狗和猴中的药代动力学参数,所有种类中均显示出良好的生物利用度。在啮齿动物中,随着p.o.剂量的增加观察到显著的非线性药代动力学。[1] BMS-536924在两周治疗后(100 mg/kg),将CD8-IGF-1R-MCF10A细胞的瘤体异种移植体体积减小到76%。[2] 70 mg/kg BMS-536924的经口给药显著抑制接种于裸鼠中的TGBC-1TKB细胞的肿瘤生长。BMS-536924上调异种移植瘤中的凋亡。治疗对小鼠的体重或死亡时的葡萄糖水平没有不良影响,表明毒性可容忍。[4] |
激酶实验 | IGF-I Pathway Activity: 1 × 106 pBabe-MCF10A cells are seeded onto 60-mm dishes. After 24 hours, the medium is changed to serum-free medium and incubated overnight at 37 °C for 24 hours. Cells are then pre-incubated with or without 1 uM BMS-536924 for 1 hour in serum free medium followed by stimulation with IGF-I (50 ng/mL) for 10 minutes. Cell monolayers are washed twice with PBS and harvested for immunoblot analysi |
细胞实验 | Cell proliferation is evaluated by [3H]thymidine incorporation after exposure to BMS-536924 for 72 hours. Cells are plated at an optimized density in 96-well plates, incubated overnight at 37 °C, and then exposed to a serial dilution of the drug. After a 72-hours incubation, cells are pulsed with 4 μCi/mL [3H]thymidine for 3 hours, trypsinized, harvested onto UniFilter-96 GF/B plates; scintillation is measured on a TopCount NXT. Results are expressed as an IC50. The mean IC50 and SD from multiple tests for each cell line are calculated. (Only for Reference) |
别名 | 胰岛素样生长因子-1 受体拮抗剂, HY-10262, CS-0117, BMS 536924 |
分子量 | 479.96 |
分子式 | C25H26ClN5O3 |
CAS No. | 468740-43-4 |
Smiles | Cc1cc(cc2nc([nH]c12)-c1c(NC[C@@H](O)c2cccc(Cl)c2)cc[nH]c1=O)N1CCOCC1 |
密度 | 1.44 g/cm3 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
溶解度信息 | Ethanol: < 1 mg/mL (insoluble or slightly soluble) H2O: < 1 mg/mL (insoluble or slightly soluble) DMSO: 89 mg/mL (185.4 mM) | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容